PLUS1
79.55
1.93 (2.49%)
1.93 (2.49%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Axsome Therapeutics Inc | AXSM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 1.93 | 2.49% | 79.55 | 77.79 | 80.25 | 77.79 | 77.62 | 13:13:28 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 79.60 | 79.67 | 0.07 | 0.09% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,802 | 178,272 | $ 79.32 | $ 14,140,060 | 506,584 | 13.64 - 125.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:13:23 | 2 | $ 79.67 | USD |
Axsome Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.95B | 37.08M | 28.84M | $ - | $ - | -2.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Axsome Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/10/2020 | 08:24 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/10/2020 | 07:05 | GlobeNewswire Inc. | Axsome Therapeutics Reports Second Quarter 2020 Financial.. |
| 8/10/2020 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics Announces Further Progress in AXS-05.. |
| 8/05/2020 | 07:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/05/2020 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics Receives FDA Breakthrough Therapy.. |
| 7/30/2020 | 07:00 | GlobeNewswire Inc. | Axsome Therapeutics to Report Second Quarter 2020 Financial.. |
| 7/13/2020 | 07:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AXSM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 77.50 | 83.48 | 74.83 | 78.36 | 405,739 | 2.05 | 2.65% |
| 1 Month | 80.27 | 85.25 | 70.52 | 78.12 | 367,897 | -0.72 | -0.9% |
| 3 Months | 84.52 | 89.26 | 69.77 | 78.89 | 500,017 | -4.97 | -5.88% |
| 6 Months | 93.23 | 125.25 | 35.44 | 74.86 | 755,585 | -13.68 | -14.67% |
| 1 Year | 25.48 | 125.25 | 13.64 | 62.31 | 948,056 | 54.07 | 212.21% |
| 3 Years | 5.35 | 125.25 | 1.94 | 32.98 | 766,414 | 74.20 | 1,386.92% |
| 5 Years | 9.00 | 125.25 | 1.94 | 31.19 | 521,064 | 70.55 | 783.89% |
Axsome Therapeutics Description
| Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and others. |
